Literature DB >> 11964299

Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.

Michael S von Bergwelt-Baildon1, Robert H Vonderheide, Britta Maecker, Naoto Hirano, Karen S Anderson, Marcus O Butler, Zhinan Xia, Wan Y Zeng, Kai W Wucherpfennig, Lee M Nadler, Joachim L Schultze.   

Abstract

CD40 engagement is the major signal that induces B cells to efficiently present antigen to T cells. We previously demonstrated that human peripheral blood-derived CD40-activated B cells (CD40-B cells) function as antigen-presenting cells (APCs). Here, we have established a culture system to generate these APCs under clinically applicable conditions using guanylic acid-grade soluble trimeric CD40 ligand. To monitor APC function and antigen loading for these cells, simple and efficient quality control assays have been developed. Using this approach, we demonstrate that CD40-B cells from healthy donors and cancer patients are fully functional and equally expanded in long-term cultures. These B cells boost robust memory T-cell responses, but more importantly, they also prime naive T-cell responses against neoantigens ex vivo. CD40-B cells overcome current obstacles, such as the difficulty of isolation, generation, and long-term expansion observed with other APCs. Therefore, they are an excellent source of professional APCs for immune assessment, antigen discovery, and antigen-specific immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11964299     DOI: 10.1182/blood.v99.9.3319

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  63 in total

1.  In vitro and in vivo imaging of initial B-T-cell interactions in the setting of B-cell based cancer immunotherapy.

Authors:  Nela Klein Gonzalez; Kerstin Wennhold; Sandra Balkow; Eisei Kondo; Birgit Bölck; Tanja Weber; Maria Garcia-Marquez; Stephan Grabbe; Wilhelm Bloch; Michael von Bergwelt-Baildon; Alexander Shimabukuro-Vornhagen
Journal:  Oncoimmunology       Date:  2015-06-17       Impact factor: 8.110

2.  Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells.

Authors:  G A Van den Bosch; P Ponsaerts; G Nijs; M Lenjou; G Vanham; D R Van Bockstaele; Z N Berneman; V F I Van Tendeloo
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

3.  Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells.

Authors:  Denis Leclerc; Diane Beauseigle; Jérome Denis; Hélène Morin; Christine Paré; Alain Lamarre; Réjean Lapointe
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

4.  Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity.

Authors:  Naoto Hirano; Marcus O Butler; Zhinan Xia; Sascha Ansén; Michael S von Bergwelt-Baildon; Donna Neuberg; Gordon J Freeman; Lee M Nadler
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

5.  Analysis of two-dimensional dissociation constant of laterally mobile cell adhesion molecules.

Authors:  De-Min Zhu; Michael L Dustin; Christopher W Cairo; David E Golan
Journal:  Biophys J       Date:  2006-11-03       Impact factor: 4.033

6.  4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.

Authors:  Hua Zhang; Kristen M Snyder; Megan M Suhoski; Marcela V Maus; Veena Kapoor; Carl H June; Crystal L Mackall
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

7.  Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.

Authors:  Sonja Obermann; Susanne Petrykowska; Michael P Manns; Firouzeh Korangy; Tim F Greten
Journal:  Immunology       Date:  2007-04-30       Impact factor: 7.397

8.  Induced pluripotent stem cell reprogramming by integration-free Sendai virus vectors from peripheral blood of patients with craniometaphyseal dysplasia.

Authors:  I-Ping Chen; Keiichi Fukuda; Noemi Fusaki; Akihiro Iida; Mamoru Hasegawa; Alexander Lichtler; Ernst J Reichenberger
Journal:  Cell Reprogram       Date:  2013-11-12       Impact factor: 1.987

9.  CD40-activated B cells are more potent than immature dendritic cells to induce and expand CD4(+) regulatory T cells.

Authors:  Jian Zheng; Yinping Liu; Yu-Lung Lau; Wenwei Tu
Journal:  Cell Mol Immunol       Date:  2010-01       Impact factor: 11.530

10.  Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.

Authors:  Zhiyuan Lin; Li Liu; Yu Xia; Xiang Chen; Ying Xiong; Yang Qu; Jiajun Wang; Qi Bai; Jianming Guo; Jiejie Xu
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.